Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × cemiplimab × Lymphoid × Clear all

Phase

Status

Recruiting 4 Withdrawn 2 Terminated 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 9 Dermatologic 7 Head & Neck 4 Tumor-Agnostic 3 Plasma cell 1 Lymphoid 1 Genitourinary 1 Gastrointestinal 1 CNS 1 Breast 1

Conditions

Recurrence 1 Lymphoma, B-Cell 1

Interventions

Cyclophosphamide 118 Rituximab 112 Doxorubicin 62 Vincristine 58 Prednisone 53 venetoclax 50 fludarabine 46 ibrutinib 45 Lenalidomide 42 Specimen Handling 40 Biopsy 39 obinutuzumab 37 Etoposide 36 acalabrutinib 34 fludarabine phosphate 33 CT-P10 31 Magnetic Resonance Spectroscopy 30 Cytarabine 28 Bendamustine Hydrochloride 27 Methotrexate 26 Dexamethasone 25 Nivolumab 22 zanubrutinib 19 prednylidene 17 pembrolizumab 17 deltacortene 17 Melphalan 17 Calcium Dobesilate 17 Brentuximab Vedotin 16 blinatumomab 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02651662 2026-02-02

CLIO-1

Regeneron Pharmaceuticals

Phase 1 Active not recruiting

Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡